ALNY vs. BMY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and BMY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
BMY’s market capitalization of 95.49 billion USD is significantly greater than ALNY’s 43.28 billion USD, highlighting its more substantial market valuation.
BMY carries a higher beta at 0.39, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
| Symbol | ALNY | BMY |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| CEO | Yvonne L. Greenstreet | Christopher S. Boerner |
| Price | 331.91 USD | 46.92 USD |
| Market Cap | 43.28 billion USD | 95.49 billion USD |
| Beta | 0.21 | 0.39 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | June 1, 1972 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALNY and BMY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
BMY
31.93%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
BMY’s Return on Equity of 31.93% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
BMY
10.85%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
BMY’s Return on Invested Capital of 10.85% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
BMY
11.38%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
Falling into the lower quartile for the Drug Manufacturers - General industry, BMY’s Net Profit Margin of 11.38% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
BMY
18.45%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
BMY’s Operating Profit Margin of 18.45% is in the lower quartile for the Drug Manufacturers - General industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | ALNY | BMY |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 31.93% |
| Return on Assets (TTM) | -6.40% | 5.86% |
| Return on Invested Capital (TTM) | -2.79% | 10.85% |
| Net Profit Margin (TTM) | -11.49% | 11.38% |
| Operating Profit Margin (TTM) | -4.91% | 18.45% |
| Gross Profit Margin (TTM) | 86.01% | 65.99% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
BMY
1.28
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
BMY’s Current Ratio of 1.28 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
BMY
2.95
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
BMY’s leverage is in the upper quartile of the Drug Manufacturers - General industry, with a Debt-to-Equity Ratio of 2.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
BMY
4.36
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
BMY’s Interest Coverage Ratio of 4.36 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALNY | BMY |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.28 |
| Quick Ratio (TTM) | 2.98 | 1.17 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 2.95 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.55 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 2.49 |
| Interest Coverage Ratio (TTM) | -0.79 | 4.36 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and BMY. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
BMY
5.24%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
With a Dividend Yield of 5.24%, BMY offers a more attractive income stream than most of its peers in the Drug Manufacturers - General industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
BMY
90.59%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
BMY’s Dividend Payout Ratio of 90.59% is in the upper quartile for the Drug Manufacturers - General industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ALNY | BMY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 5.24% |
| Dividend Payout Ratio (TTM) | 0.00% | 90.59% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
BMY
17.59
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
BMY’s P/E Ratio of 17.59 is within the middle range for the Drug Manufacturers - General industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
BMY
-3.05
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
BMY has a negative Forward PEG Ratio of -3.05. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
BMY
2.00
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
BMY’s P/S Ratio of 2.00 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
BMY
5.48
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | ALNY | BMY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 17.59 |
| Forward PEG Ratio (TTM) | -43.29 | -3.05 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 2.00 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | 5.48 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 7.30 |
| EV-to-EBITDA (TTM) | -285.32 | 8.39 |
| EV-to-Sales (TTM) | 18.55 | 2.85 |